BIOC:NSD-Biocept Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.55

Change

+0.01 (+0.65)%

Market Cap

USD 0.03B

Volume

0.07M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Biocept Inc (BIOC) Stock Analysis:
Based on the Biocept Inc stock forecasts from 0 analysts, the average analyst target price for Biocept Inc is not available over the next 12 months. Biocept Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biocept Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Biocept Inc’s stock price was USD 1.55. Biocept Inc’s stock price has changed by -6.06% over the past week, -15.30% over the past month and -65.01% over the last year.

About

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
IDXX IDEXX Laboratories Inc

-1.98 (-0.55%)

USD30.43B 42.11 28.03
ICLR ICON Public Limited Company

-0.48 (-0.23%)

USD17.15B 94.41 27.29
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
EXAS Exact Sciences Corporation

-1.74 (-3.33%)

USD9.20B N/A N/A
SYNH Syneos Health Inc

-0.15 (-0.21%)

USD7.19B 30.32 15.99
MEDP Medpace Holdings Inc

+0.47 (+0.34%)

USD4.48B 24.90 19.21
LNTH Lantheus Holdings Inc

+2.89 (+4.52%)

USD4.09B 2,335.00 197.83
GH Guardant Health Inc

-0.82 (-2.28%)

USD3.66B N/A N/A
NEOG Neogen Corporation

-0.53 (-2.00%)

USD2.85B 57.94 29.29
NTRA Natera Inc

-0.28 (-0.82%)

USD2.78B N/A N/A

ETFs Containing BIOC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.18% 36% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.18% 36% F 18% F
Trailing 12 Months  
Capital Gain -65.48% 56% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.48% 56% F 22% F
Trailing 5 Years  
Capital Gain -99.63% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.63% 3% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -46.66% 2% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.66% 2% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.69% 61% D- 30% F
Risk Adjusted Return -93.89% 2% F 2% F
Market Capitalization 0.03B 20% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.82 70% C- 65% D
Price/Book Ratio 0.65 95% A 88% B+
Price / Cash Flow Ratio -1.32 50% F 58% F
EV/EBITDA 35.01 26% F 17% F
Management Effectiveness  
Return on Equity -9.23% 66% D 41% F
Return on Invested Capital -64.76% 23% F 16% F
Return on Assets -2.79% 71% C- 39% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.91 66% D 52% F
Short Percent 1.84% 80% B- 61% D-
Beta 0.48 88% B+ 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.